We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clearstream | LSE:CTN | London | Ordinary Share | IE00B03QHM52 | ORD EUR0.125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 84.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCTN
RNS Number : 9875A
ClearStream Technologies Group PLC
10 February 2011
For Immediate release 10 February 2011
ClearStream Technologies Group plc
("ClearStream" or "the Company")
Trading Statement
ClearStream Technologies Group plc ("ClearStream") the specialist global supplier of medical devices used in coronary and peripheral interventional procedures, announces the following trading update in advance of the publication of its interim results to 31 January 2011 which are expected to be announced on March 24 2011.
The Board is pleased to report that ClearStream has enjoyed a good start to the year and that at the half year point results are anticipated to be comfortably in line with market expectations for the full year to 31 August 2011.
The improvements and expansions introduced during 2010 into the Company's production lines to increase flexibility and consistency in manufacturing and to provide the additional capacity needed to meet the growth in demand for its products, have been successfully integrated. Yields, through put and gross margins are all showing progressive improvement. The Company now operates the equivalent of nine production lines and plans to introduce an additional line during the next quarter. With the recently announced support of Enterprise Ireland, ClearStream has acquired additional factory space to service the current and forecast increases in production and is planning to invest in further R&D to maintain its leading position in the peripheral intervention area The new facilities are expected to be operational by June.
During the period, sales of co-label and OEM products have been very healthy and, following a slower start, sales of own brand products are now trending upwards. Cash flows are healthy and the Company has been able to fund the expansion in its activities without resort to external finance.
Traditionally, ClearStream enjoys stronger trading in the second half of its financial year and the Directors anticipate a good performance during the second half of the current year driven by further demand for OEM product, the successful launch by Cordis, on a co-label basis, of the new, ground-breaking Sleek OTW catheter in North America and continued momentum in its own brand product sales.
For further information:
ClearStream Technologies Group Tel: + 353 (0) 53 923 plc 7111 Andrew Jones, CEO Winningtons Financial Tel: + 44 (0) 117 985 8989 Paul Vann FinnCap Tel: + 44 (0) 20 7600 1658 Marc Young, Corporate Finance Charlotte Stranner, Corporate Finance Stephen Norcross, Corporate Broking
About ClearStream:
ClearStream, , based in Enniscorthy, Co Wexford, Ireland, is an innovative maker of medical devices used in peripheral (lower limb) and coronary interventional procedures, including catheters and stents. Its products are sold under ClearStream's own brands and are also supplied to Original Equipment Manufacturers.
The Company is listed on the AIM market of the London Stock Exchange.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLFFIVFRIAIIL
1 Year Clearstream Chart |
1 Month Clearstream Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions